ST. PAUL, Minn., Nov. 6 (UPI) -- Positive results from a late-stage clinical trial released Thursday have raised hopes that type 1 diabetes patients who suffer from chronic kidney disease will have a new treatment for the first time in decades. The results of the Phase 3 trial, unveiled at American Society of Nephrology annual conference in Houston, found that the drug finerenone, made by pharma giant Bayer and marketed under the brand name Kerendia, is safe and effective in treating type 1